🇺🇸 Levocabastine HCL in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 11

Most-reported reactions

1. International Normalised Ratio Increased — 2 reports (18.18%)
2. Arthralgia — 1 report (9.09%)
3. Chest Pain — 1 report (9.09%)
4. Cough — 1 report (9.09%)
5. Drug Exposure During Pregnancy — 1 report (9.09%)
6. Drug Interaction — 1 report (9.09%)
7. Dry Mouth — 1 report (9.09%)
8. Dyspnoea — 1 report (9.09%)
9. Hallucination — 1 report (9.09%)
10. Hypoglycaemia — 1 report (9.09%)

Source database →

Frequently asked questions

Is Levocabastine HCL approved in United States?

Levocabastine HCL does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Levocabastine HCL in United States?

Chong Kun Dang Pharmaceutical is the originator. The local marketing authorisation holder may differ — check the official source linked above.